SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq:
NUVA), a medical device company focused on developing products for minimally
disruptive surgical treatments for the spine, announced today that Alex
Lukianov, Chairman and Chief Executive Officer, is scheduled to present at the
27th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel
in San Francisco, CA on Tuesday, January 13, 2009, at 11:00 a.m. PT.
A live Web cast of the presentation will be available online from the
investor relations page of the Company's corporate Web site at
www.nuvasive.com. After the live Web cast, the presentation will remain
available on NuVasive's Web site, www.nuvasive.com, for 30 days.
NuVasive is a medical device company focused on the design, development
and marketing of products for the surgical treatment of spine disorders. The
Company's product portfolio is focused on applications in the over $4.2
billion U.S. spine fusion market. The Company's current principal product
offering includes a minimally disruptive surgical platform called Maximum
Access Surgery, or MAS(R), as well as a growing offering of cervical and
motion preservation products.
The MAS platform offers advantages for both patients and surgeons such as
reduced surgery and hospitalization time and faster recovery. MAS combines
three categories of current product offerings: NeuroVision(R) a proprietary
software-driven nerve avoidance system; MaXcess(R) a unique split-blade design
retraction system; and specialized implants, like SpheRx(R) and CoRoent(R),
that collectively minimize soft tissue disruption during spine surgery while
allowing maximum visualization and surgical reproducibility. NuVasive's
product offering is also focused on cervical internal fixation products and
its R&D pipeline emphasizes both MAS and motion preservation.
NuVasive cautions you that statements included in this press release that
are not a description of historical facts are forward-looking statements that
involve risks, uncertainties, assumptions and other factors which, if they do
not materialize or prove correct, could cause NuVasive's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. The potential risks and uncertainties that could
cause actual growth and results to differ materially include, but are not
limited to: the uncertain process of seeking regulatory approval or clearance
for NuVasive's products or devices, including risks that such process could be
significantly delayed; the possibility that the FDA may require significant
changes to NuVasive's products or clinical studies; the risk that products may
not perform as intended and may therefore not achieve commercial success; the
risk that competitors may develop superior products or may have a greater
market position enabling more successful commercialization; the risk that
additional clinical data may call into question the benefits of NuVasive's
products to patients, hospitals and surgeons; and other risks and
uncertainties more fully described in NuVasive's press releases and periodic
filings with the Securities and Exchange Commission. NuVasive's public filings
with the Securities and Exchange Commission are available at www.sec.gov.
NuVasive assumes no obligation to update any forward-looking statement to
reflect events or circumstances arising after the date on which it was made.
SOURCE NuVasive, Inc.
CONTACT: Kevin C. O'Boyle, EVP & Chief Financial Officer of NuVasive,
Inc., +1-858-909-1998, email@example.com, or Investors: Steve
Ogilvie, Sr. Dir., Business Development & Investor Relations of NuVasive,
Inc., +1-858-638-5556, firstname.lastname@example.org; or Media: Jason Rando
of The Ruth Group, +1-646-536-7025, email@example.com, for NuVasive,
Web Site: http://www.nuvasive.com